Shouval, Daniel

Publishing since 1976 (Dinosaur)

Has published 176 publications in 35 years

Number of publications published per year by Shouval, Daniel. (Source : PubMed)

Distribution of publications types for Shouval, Daniel. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Shouval D. Focus.  J. Hepatol.  2010;52;4  
•  Shouval D. The impact of ribavirin treatment on spermatogenesis in patients with chronic hepatitis C.  J. Hepatol.  2010  
•  Mizrahi M, Adar T, Shouval D, Bloom AI, Shibolet O. Endotipsitis-persistent infection of transjugular intrahepatic portosystemic shunt: pathogenesis, clinical features and management.  Liver Int.  2010;30;2  
•  Shouval D. Focus.  J. Hepatol.  2010;52;2  
•  Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.  J. Hepatol.  2009;50;2  
•  Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview.  Vaccine  2008;26;49  
•  Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection.  J. Hepatol.  2008;49;4  
•  Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, Ropero AM, Shouval D, Ward W, Van Damme P. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology.  J. Viral Hepat.  2008;15 Suppl 2  
•  Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, Flisiak R, Rehak V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.  Hepatology  2008;48;2  
•  Mizrahi M, Lalazar G, Ben Ya'acov A, Livovsky DM, Horowitz Y, Zolotarov L, Adler R, Shouval D, Ilan Y. Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination.  Vaccine  2008;26;21  

[ See timeline ] [ See all publications ]